
GYRE Stock Forecast & Price Target
GYRE Analyst Ratings
Bulls say
Gyre Therapeutics Inc. is well-positioned for growth through its acquisition of generic nintedanib, which is expected to enhance its capital resources and solidify its leadership in the idiopathic pulmonary fibrosis (IPF) market. This strategic move is likely to provide significant support for Gyre's operations amid challenging market conditions, reinforcing its commitment to addressing both lung and liver fibrosis through a diverse portfolio of therapies. Additionally, the company’s focus on commercial-stage products and ongoing development of treatments for MASH-associated liver fibrosis exhibits a robust potential for revenue generation in the future.
Bears say
Gyre Therapeutics Inc. faces a negative outlook primarily due to depressed forward multiples, attributed to ongoing market volatility, which raises concerns about the company's valuation. The company's reliance on non-growth stage assets, such as the commercial sales of pirfenidone in China, further exacerbates this issue, as projected revenue generation from these products has plateaued. Additionally, cash burn may pose significant risks, influenced by the stages of development programs and uncertain revenue from potential partnerships or collaborative agreements.
This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
GYRE Analyst Forecast & Price Prediction
Start investing in GYRE
Order type
Buy in
Order amount
Est. shares
0 shares